Stem Cell Therapy: What Works, What Doesn't, and What It's Worth

Stem cell therapy: what is proven, what is promising, and what is being oversold

Regenerative medicine is the most exciting area I work in and the most exaggerated area in all of medicine. Both of those things are true at once. In two decades of practicing medicine I have watched patients spend five figures on injections that had no chance of doing what they were promised. I have also watched fat transfer restore a face in a way no filler could. The difference between those two outcomes is knowing which procedure has evidence behind it.

So here is the honest map, area by area, including the parts that are inconvenient for a clinic that offers regenerative procedures.

Start with what a stem cell actually does

The original idea was that you inject stem cells, they take up residence, and they turn into new cartilage or new tissue. That story is mostly wrong, and the correction matters.

Roughly 80 percent of transplanted cells die within three days. The hostile environment of an injured joint is not a welcoming place. What benefit does occur appears to come mainly from paracrine signaling — the cells release growth factors, cytokines, and small vesicles that stimulate blood vessel growth, limit scarring, calm inflammation, and recruit your own repair cells before dying off. They are less a construction crew than a signal flare.

That is why researchers are now studying cell-free products — just the secreted signals, no cells. And it explains why results are modest rather than miraculous. You are not growing a new knee. You are sending a message to the tissue you still have.

One more piece of context: the only mature, proven stem cell therapy in medicine is bone marrow transplantation for blood cancers and blood disorders. Everything else on this page is investigational to some degree. Anyone who tells you otherwise is selling.

Knee arthritis: is it worth the money?

This is the most common question I get, and the evidence here is unusually good — good enough to answer honestly.

Comparison	What the best evidence shows
Stem cells vs. hyaluronic acid (gel shots)	Stem cells win on symptoms. The 2025 Cochrane review found about 1.5 points better pain relief on a 0–10 scale at 6–12 months — but rated the evidence uncertain, citing imprecision and suspected publication bias.
Stem cells vs. PRP	No meaningful difference. Cochrane found it uncertain whether stem cells beat PRP at any time point. Two 24-month randomized trials found bone marrow concentrate and microfragmented fat were each equivalent to PRP.
PRP vs. hyaluronic acid	PRP wins, consistently, across multiple high-quality meta-analyses at 6 and 12 months. Leukocyte-poor PRP performs best.
Any of them vs. cartilage regrowth	None of them reliably regenerates cartilage. Imaging results are inconsistent.

Now the caveat that should shape your decision, because almost nobody selling these will say it. Statistically better is not the same as noticeably better. The recurring finding across the highest-quality analyses is that the advantage of stem cells over gel shots usually fails to exceed the minimal clinically important difference — the threshold at which a patient can actually feel the change. One meta-analysis found stem cell injections were statistically better than hyaluronic acid on pain scores, yet the same preparations were no better than placebo, and the share of patients crossing the meaningful-improvement line did not differ.

My read: PRP and stem cell injections perform about the same for knee arthritis. PRP costs far less, is far more standardized, and has a gentler side effect profile. Cell-based injections cause more transient pain and swelling and remain non-standardized for this use. If someone is quoting you many thousands of dollars for a knee injection on the promise that it will regrow cartilage, the evidence does not support the promise or the price.

Facial fat transfer: this one is real

Facial fat grafting is a different category, and I want to be as clear about its strengths as I was about the knee’s limits. This is an established surgical technique with a strong track record.

The reasoning behind it is sound. A face does not just sag with age; it deflates. Discrete fat compartments lose volume, the underlying bone remodels, and projection is lost. Refilling those compartments restores three-dimensional contour in a way that pulling skin tighter cannot. Fat is your own tissue, it integrates with the surrounding tissue, and it is abundant.

What the literature reports: durable correction, satisfaction rates in the range of 73 to 90 percent, and lasting contour improvement — with the honest asterisk that roughly 5 to 16 percent of patients need a second session to reach the result they wanted. Retention varies by area, and mobile regions like around the mouth resorb more than still ones. Technique matters enormously: small amounts deposited across multiple passes and planes, using low pressure and blunt cannulas.

Most complications are minor and temporary — swelling, bruising, some asymmetry. The rare serious one deserves naming: injection into a blood vessel, which can cause skin death or vision loss. That risk is why blunt cannulas, low injection pressure, and an experienced hand are not optional details. Ask whoever is doing your procedure about it. If they wave the question off, find someone else.

Fat transfer to the breast, and the cancer question

This is the most important safety conversation in the whole field, and it deserves more nuance than a yes or no.

The clinical data are reassuring. Standard autologous fat grafting has been studied extensively in women with a history of breast cancer, and the evidence consistently shows no increase in recurrence.

The laboratory data are not. In cell culture and animal models, adipose-derived stem cells can promote breast cancer growth through several mechanisms — supporting cancer stem cell properties, driving inflammatory signaling, encouraging blood vessel growth and immune evasion. One meta-analysis combined both literatures and reached exactly this split conclusion: fat grafting did not raise recurrence risk clinically, but the stem cells themselves "should be used with caution." Findings are not uniformly alarming — at least one model found the opposite — which tells you how model-dependent this is.

Here is the distinction that matters clinically. Plain fat grafting and stem-cell-enriched fat grafting are not the same procedure, and they do not have the same evidence base. A 2026 meta-analysis of enriched versus conventional grafting in breast reconstruction found recurrence rates of 5.3 percent versus 3.4 percent — but the confidence interval ran from 0.10 to 24.3. A range that wide means the study could not answer the question at all. There were too few events and too little enrichment-specific data.

So: fat grafting after breast cancer appears oncologically safe. Deliberately concentrating stem cells into a graft placed near a former tumor bed is a different decision, with thinner and shorter follow-up, and it belongs in a careful conversation with your oncologist and your surgeon — not in a marketing brochure.

Hair restoration and skin quality

Both of these are listed in every regenerative medicine brochure. Both have weaker evidence than the marketing suggests.

Hair restoration appears in the literature as a genuine area of investigation for adipose-derived cells, alongside wound healing, burns, scarring, and radiation damage. Investigation is the right word. It is not an established indication with the kind of trial support that would let me promise you a result.

Skin quality is more instructive. A systematic review of facial fat grafting for skin quality — texture, elasticity, pigmentation, separate from volume — found that while most individual studies reported improvement, the level of evidence was low, and the review concluded that fat grafting and stem cell injection "hardly seemed" to reliably improve skin quality. It was consistently safe. Safe and effective are two different claims, and the field routinely blurs them.

The regulatory line most clinics do not explain

There is a real legal and scientific difference between two things that get called the same name.

Stromal vascular fraction (SVF) is what you get by processing fat at the point of care on the same day. It is a mixed population — and only about 1 to 10 percent of it is actually stem cells. The rest is blood vessel cells, immune cells, fibroblasts, and precursors.
Culture-expanded stem cells are grown in a lab over days to weeks into a purer, more potent population. In the United States these are generally regulated as more-than-minimally-manipulated cellular products, which means they require clinical trials and FDA approval like a drug.

The literature itself constantly conflates the two, which is one reason study results are so inconsistent. If a clinic is advertising "stem cell therapy," a fair question is which of these they are actually giving you, and under what regulatory status. Many commercially marketed stem cell clinics offer unproven, non-FDA-approved products for conditions where efficacy has never been established.

Where I land

I offer regenerative procedures, and I believe in them where the evidence supports them. Fat transfer for facial volume is excellent and I stand behind it. PRP is well-studied, affordable, and useful. Both are things I do.

What I will not do is quote you a large number for an injection that the best available research says performs about the same as a cheaper one, or tell you a procedure regrows tissue when the data say it sends a signal. The field is moving quickly and I follow it closely. When the evidence catches up to the marketing, I will be the first to say so.

Measure, don’t guess

Before any regenerative procedure, the questions worth answering are what is actually causing the problem, what your inflammatory and metabolic status looks like, and whether something simpler and better-proven should come first. A knee that hurts because of untreated metabolic disease and deconditioning will not be fixed by an injection of any kind. Related reading: integrative care for rheumatoid arthritis, amino acids, collagen, and glycine, peptide therapy and what is legal, and facial injection safety.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

References

This page covers general health information and is not a substitute for individual medical advice. It does not promise any outcome. If you have a history of cancer, discuss any grafting or cell-based procedure with your oncologist before proceeding.

The New England Journal of Medicine, 2019 — stem cells in the treatment of disease.
Signal Transduction and Targeted Therapy, 2022 — stem cell-based therapy for human diseases.
Cochrane Database of Systematic Reviews, 2025 — stem cell injections for osteoarthritis of the knee.
Arthroscopy, 2026 — intra-articular orthobiologics show statistically but not clinically meaningful improvements versus viscosupplementation: network meta-analysis.
Arthroscopy, 2021 — intra-articular mesenchymal stromal cell injections are no different from placebo in knee osteoarthritis.
The American Journal of Sports Medicine, 2022 — bone marrow aspirate concentrate is equivalent to platelet-rich plasma at 2 years.
The American Journal of Sports Medicine, 2022 — microfragmented adipose tissue versus platelet-rich plasma at 2-year follow-up.
The American Journal of Sports Medicine, 2021 — platelet-rich plasma versus hyaluronic acid for knee osteoarthritis.
Plastic and Reconstructive Surgery, 2024 — technical precision with autologous fat grafting for facial rejuvenation.
Plastic and Reconstructive Surgery, 2021 — modern fat grafting techniques to the face and neck.
Plastic and Reconstructive Surgery, 2019 — the effects of facial lipografting on skin quality: systematic review.
Plastic and Reconstructive Surgery, 2026 — adipose-derived stem cell-enhanced versus conventional fat grafting for breast reconstruction.
Aesthetic Plastic Surgery, 2023 — meta-analysis of the oncological safety of autologous fat grafting after breast cancer.
Journal of Clinical Medicine, 2024 — autologous fat grafting: systematic review of oncological safety in breast cancer patients.
Frontiers in Cell and Developmental Biology, 2026 — advancing fat graft survival: adipose-derived stem cell mechanisms.
Stem Cell Research & Therapy, 2017 — adipose tissue-derived stromal vascular fraction: biology and translation.
Stem Cells International, 2020 — progress in stem cell therapy for spinal cord injury.
IEEE Pulse, 2021 — stem cell update: where are we now?